Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMKDEZ)

Drug Name

Beta-1-C-Butyl-1-deoxygalactonojirimycin Drug Info

Synonyms

CHEMBL1163255; beta-1-C-Butyl-1-deoxygalactonojirimycin

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Alpha-galactosidase A (GLA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pegunigalsidase alfa	DMOUW65	Fabry disease	5C56.01	Approved	[2]
Migalastat	DMFIQ2H	Fabry disease	5C56.01	Approved	[3]
AVR-RD-01	DMC1XHK	Fabry disease	5C56.01	Phase 1/2	[4]
ST-920	DMOJIPG	Fabry disease	5C56.01	Phase 1/2	[5]
4D-310	DMNG59Y	Fabry disease	5C56.01	Phase 1/2	[6]
isaralgagene civaparvovec	DM5SSPZ	Fabry disease	5C56.01	Phase 1/2	[7]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[8]
Fucose	DMAHMSV	N. A.	N. A.	Investigative	[8]
2,5-dideoxy-2,5-imino-D-altritol	DMI1O54	Discovery agent	N.A.	Investigative	[1]
Beta-1-C-butenyl-1-deoxygalactonojirimycin	DM6GTBC	Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease. Bioorg Med Chem. 2010 Jun 1;18(11):3790-4.
2	Characterization of a chemically modified plant cell culture expressed human alpha-Galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab. 2015 Feb;114(2):259-67.
3	AT-1001: a high-affinity alpha3beta4 nAChR ligand with novel nicotine-suppressive pharmacology. Br J Pharmacol. 2015 Apr;172(7):1834-45.
4	Clinical pipeline report, company report or official report of Avrobio.
5	AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction. Mol Ther Methods Clin Dev. 2020 Jul 9;18:607-619.
6	Clinical pipeline report, company report or official report of 4D Molecular Therapeutics
7	ClinicalTrials.gov (NCT04046224) A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR). U.S.National Institutes of Health.
8	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.